Literature DB >> 20541240

Acquired and congenital risk factors associated with cerebral venous sinus thrombosis.

Robert D McBane1, Alfonso Tafur, Waldemar E Wysokinski.   

Abstract

The mechanistic paradigm underlying venous thrombosis at atypical locations stems from the observation that most events occur as a result of pathology of the organ system drained by the involved venous segment. Cerebral venous sinus thrombosis stands apart as an exception to this general rule. Although brain and sinus pathology are well established causes, these combined variables account for approximately one third of cases. The marked female preponderance and strong association with gender specific risk factors including hormonal manipulation, pregnancy and the puerperium are particularly notable. Factor V Leiden and prothrombin G20210A mutations and hyperhomocysteinemia represent important risk factors particularly when combined with acquired variables. The association with oral contraception use and the prothrombin G20210A gene mutation may offer insights into the anatomic predilection for cerebral venous sinus involvement as compared to venous thrombosis of the lower extremities. The intent of this review is to summarize the corporate literature of both acquired and congenital risk factors associated with cerebral venous sinus thrombosis in order to assist clinicians in their search for underlying mechanisms and to risk stratify patients for anticoagulation treatment duration and risk of recurrent thrombosis. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20541240     DOI: 10.1016/j.thromres.2010.04.015

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

Review 1.  The clinical correlates of vaccine-induced immune thrombotic thrombocytopenia after immunisation with adenovirus vector-based SARS-CoV-2 vaccines.

Authors:  Eleanor R Gaunt; Neil A Mabbott
Journal:  Immunother Adv       Date:  2021-08-17

2.  Cerebral Venous Thrombosis and Venous Infarction: Case Report of a Rare Initial Presentation of Smoker's Polycythemia.

Authors:  Mihir Raval; Anu Paul
Journal:  Case Rep Neurol       Date:  2010-11-22

3.  Seizure in Pregnancy Following Cerebral Venous Sinus Thrombosis.

Authors:  Farnoush Farzi; Mehrsima Abdollahzadeh; Roya Faraji; Tahereh Chavoushi
Journal:  Anesth Pain Med       Date:  2015-06-22

Review 4.  Hormonal contraceptives and cerebral venous thrombosis risk: a systematic review and meta-analysis.

Authors:  Farnaz Amoozegar; Paul E Ronksley; Reg Sauve; Bijoy K Menon
Journal:  Front Neurol       Date:  2015-02-02       Impact factor: 4.003

5.  A minor role of asparaginase in predisposing to cerebral venous thromboses in adult acute lymphoblastic leukemia patients.

Authors:  Saara Roininen; Outi Laine; Marjut Kauppila; Marko Vesanen; Maria Rämet; Marjatta Sinisalo; Esa Jantunen; Marjaana Säily; Riikka Räty; Erkki Elonen; Ulla Wartiovaara-Kautto
Journal:  Cancer Med       Date:  2017-05-15       Impact factor: 4.452

6.  Early diagnosis and management of cerebral venous flow obstruction secondary to transsinus fracture after traumatic brain injury.

Authors:  Wen-Hao Wang; Jun-Ming Lin; Fei Luo; Lian-Shui Hu; Jun Li; Wei Huang
Journal:  J Clin Neurol       Date:  2013-10-31       Impact factor: 3.077

7.  Factor V Leiden, factor V Cambridge, factor II GA20210, and methylenetetrahydrofolate reductase in cerebral venous and sinus thrombosis: A case-control study.

Authors:  Mohammad Saadatnia; Mansour Salehi; Ahmad Movahedian; Seyed Ziaeddin Samsam Shariat; Mehri Salari; Marzieh Tajmirriahi; Elham Asadimobarakeh; Rasoul Salehi; Gilda Amini; Homa Ebrahimi; Ehsan Kheradmand
Journal:  J Res Med Sci       Date:  2015-06       Impact factor: 1.852

8.  Presence of red flags in patients with cerebral venous sinus thrombosis admitted to the emergency department because of headache: A STROBE compliant cohort-study.

Authors:  David García-Azorín; Mariana H G Monje; Nuria González-García; Ángel L Guerrero; Jesús Porta-Etessam
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.